Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug allergy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Drug allergy. Displaying page 2 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-004472-35 Sponsor Protocol Number: DE_LODRO_GR19 Start Date*: 2019-02-26
    Sponsor Name:Lofarma S.p.A.
    Full Title: A single arm, open label, dose-escalation study of carbamylated monomeric grass pollen drops in patients with a history of allergic rhinoconjunctivitis
    Medical condition: Graminacee pollen induced allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10001738 Allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000560-22 Sponsor Protocol Number: MT-12 Start Date*: Information not available in EudraCT
    Sponsor Name:ALK-Abelló A/S
    Full Title: A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivi...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) SK (Completed) DE (Completed) PL (Completed) ES (Ongoing) BG (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002673-22 Sponsor Protocol Number: 309189 Start Date*: 2005-03-11
    Sponsor Name:Schering AG
    Full Title: Double-blind, placebo controlled, randomized, multicenter, parallel-group study to compare the efficacy and safety of Advantan cream twice weekly with Advabas cream during a maintenance phase of 16...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10012438 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002133-36 Sponsor Protocol Number: 1401920 Start Date*: Information not available in EudraCT
    Sponsor Name:INTENDIS GmbH
    Full Title: A multicenter, randomized, double-blind clinical study to examine the efficacy and safety of Zarzenda® in comparison to Elidel® in the management of mild to moderate atopic dermatitis in children a...
    Medical condition: Mild to moderate atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003639 Atopic dermatitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022864-12 Sponsor Protocol Number: AA-10-1.01 Start Date*: 2011-04-20
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab ...
    Medical condition: Disease to be investigated: 12 patients with severe chronic urticaria (CU) with or without angioedema which continously need medical treatment As a control: 6 patients with atopy syndrome consisti...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009159 Chronic urticaria LLT
    12.1 10021247 Idiopathic urticaria LLT
    12.1 10003639 Atopic dermatitis LLT
    12.1 10031673 Other atopic dermatitis and related conditions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007323-64 Sponsor Protocol Number: P441201CD Start Date*: 2009-02-09
    Sponsor Name:Serentis Limited
    Full Title: A phase II, double-blind, vehicle controlled study to determine the efficacy, safety and toleration of SRD441 ointment in patients with atopic dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003384-38 Sponsor Protocol Number: R668-AD-1415 Start Date*: 2015-02-18
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONS...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) DE (Completed) FI (Completed) SE (Completed) GB (Completed) DK (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011132-34 Sponsor Protocol Number: AMC-MS-MTX-001 Start Date*: 2009-07-06
    Sponsor Name:Academic Medical Center, Department of dermatology
    Full Title: A 24 week multinational multi-center study consisting of a 12-week single blind study to evaluate the efficacy and safety of methotrexate versus Azathioprin treatment in adult patients with chronic...
    Medical condition: Patients with severe atopic dermatitis, defined as a score of 8-9 on the Rajka and Langeland criteria who are unresponsive, intolerant or contra-indicated to cyclisporin treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003013-96 Sponsor Protocol Number: AVXCLIN003 Start Date*: 2016-10-03
    Sponsor Name:Avexxin AS
    Full Title: A Randomised, Blinded, Placebo-controlled, Single Centre Pilot Study to evaluate the Safety and Efficacy of AVX001 3% Ointment (NG) administered Topically Once Daily to Patients with mild, moderate...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002203-34 Sponsor Protocol Number: M16-813 Start Date*: 2021-04-28
    Sponsor Name:AbbVie Deutschland
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005573-12 Sponsor Protocol Number: LP0162-1335 Start Date*: 2022-10-05
    Sponsor Name:LEO Pharma A/S
    Full Title: A single (assessor) blinded, randomised, parallel-group, monotherapy trial to evaluate the pharmacokinetic and safety of tralokinumab in children (age 2 to <12 years) with moderate-to-severe atopic...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001036-23 Sponsor Protocol Number: CASM981C2442 Start Date*: 2004-11-05
    Sponsor Name:Novartis Sverige AB
    Full Title: A 12-week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of El...
    Medical condition: atopic dermatitis (atopic eczema)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003368-64 Sponsor Protocol Number: CS-BM32-002 Start Date*: 2011-10-12
    Sponsor Name:Biomay AG
    Full Title: Safety and dose finding study based on the effects of three subcutaneous injections of BM32, a recombinant hypoallergenic grass pollen vaccine, on responses to allergen challenge by skin testing an...
    Medical condition: Grass pollen allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003454-29 Sponsor Protocol Number: CYT005-AllQbG10 04 Start Date*: 2007-10-19
    Sponsor Name:Cytos Biotechnology AG
    Full Title: Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity and Clinical Efficacy of a Specific Immuotherapy Combining Allergen with CYT003-QbG10 (CYT005-AllQbG10) in...
    Medical condition: Adult patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063527 Allergic respiratory symptom LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000467-16 Sponsor Protocol Number: SP14019-18 Start Date*: 2016-06-16
    Sponsor Name:Spherium Biomed
    Full Title: EVALUATION OF SP14019-F-01 TOPICAL SOLUTION FOR THE TREATMENT OF ATOPIC DERMATITIS. PILOT STUDY (CYCLATOP STUDY)
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003881-15 Sponsor Protocol Number: AN005T Start Date*: 2013-12-31
    Sponsor Name:Anergis SA
    Full Title: Long-term, up to 3-year follow-up of a multicentre, randomized, double-blind, placebo-controlled trial (AN004T) assessing the efficacy and tolerability of 2 dosing regimens of AllerT, a combination...
    Medical condition: Long-term follow-up of desensitization by Specific ImmunoTherapy (SIT) received during the trial AN004T in subjects allergic to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) SE (Prematurely Ended) LV (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005057-39 Sponsor Protocol Number: ZPL389/101 Start Date*: 2015-04-10
    Sponsor Name:Ziarco Pharma Ltd
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFECTS OF 8 WEEKS TREATMENT WITH ORAL ZPL-3893787 (30 MG OD X 56 DAYS) ON PRURITUS IN ADULT SUBJECTS WITH MODE...
    Medical condition: Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002777-29 Sponsor Protocol Number: M17-377 Start Date*: 2022-10-14
    Sponsor Name:AbbVie Inc
    Full Title: A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects in Japan with Moderate to S...
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-000434-42 Sponsor Protocol Number: M22-000 Start Date*: 2022-08-09
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3b/4 Randomized, Double-blind, Dose-Flexibility Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis (Flex-Up)
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) SK (Trial now transitioned) FR (Completed) NL (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000747-76 Sponsor Protocol Number: LP0162-1346 Start Date*: 2018-11-20
    Sponsor Name:LEO Pharma A/S
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase 3 trial investigating the efficacy, safety, and tolerability of tralokinumab administered in combination with top...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) GB (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 00:54:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA